<DOC>
	<DOCNO>NCT01378910</DOCNO>
	<brief_summary>CCR5 antagonist might adequate alternative HIV-1-infected individual suppress viremia experience antiretroviral-related toxicity . The assessment HIV-1 tropism proviral DNA could helpful inform subject CCR5 antagonist could efficacious .</brief_summary>
	<brief_title>Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia</brief_title>
	<detailed_description>The assessment HIV-1 tropism need start treatment CCR5-antagonist . Several phenotypic genotyping tropism test develop recent year . Phenotypic assay ( i.e . TrofileTM ES-TrofileTM ) used.in clinical trial . Genotypic tropism testing , however , easy , cheap faster phenotypic method , perform local HIV laboratory . Viral RNA amplification difficult subject HIV-1 RNA level &lt; 500-1000 copies/mL . In case , optimal source genetic material peripheral blood mononuclear cell ( PBMC ) -associated proviral DNA . Whereas genotypic tropism test proviral DNA technically feasible , validated tool predict sustain virological response CCR5-antagonist therapy subject undetectable viremia . As today , maraviroc CCR5-antagonist approve HIV treatment . It drug interaction good security profile , particularly term lipid glucose metabolism . Therefore , might adequate alternative HIV-1-infected individual suppress viremia experience antiretroviral-related toxicity metabolic problem . This study evaluate 48-week virological outcome aviremic subject R5 virus proviral genotypic tropism test switch `` third drug '' regimen maraviroc .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>1 . HIV1 infect patient . 2 . Age 18 . 3 . Antiretroviral treatment contain 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors ( NRTIs ) plus 1 Nonnucleoside reversetranscriptase inhibitor ( NNRTI ) 1 protease inhibitor ( PI ) 1 integrase inhibitor ( ININ ) 4 . Patients receive stable antiretroviral treatment least 6 month . 5 . Viral load 50 copies/mL last 6 month 6 . Patients CCR5 tropism base V3 genotyping proviral DNA use G2P false positive rate 10 % interpretation method . 7 . A change treatment need due toxicity / tolerability problem 3rd drug ( PI , NNRTI ININ ) , accord investigator criterion . 8 . An antiretroviral regimen contain CCR5antagonist suitable patient ( physician criterion ) . 9 . Voluntary write informed consent . 1 . Pregnancy breastfeed . 2 . Patient previously treat maraviroc . 3 . Patients document resistance maraviroc drug consider new ARV regimen . 4 . Viral failure moment inclusion . 5 . Bad adherence history anticipate ( investigator criterion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>TROPISM</keyword>
	<keyword>PBMC</keyword>
	<keyword>GENOTYPE</keyword>
	<keyword>454 SEQUENCING</keyword>
</DOC>